Researcher
Sofie Joris
- Research Expertise:
Cancer therapy and genetics.
Familial cancer
- Keywords:Medicine
- Disciplines:Cancer diagnosis, Cancer prevention, Cancer therapy
- Users of research expertise:
Cancer therapy and genetics.
Familial cancer
Affiliations
- Laboratory for Medical and Molecular Oncology (Research group)
Member
From22 Mar 2021 → Today - Faculty of Medicine and Pharmacy (Faculty)
Member
From19 Mar 2020 → Today - Medical Oncology (Department)
Member
From1 Aug 2017 → Today - Clinical sciences (Department)
Member
From15 Apr 2021 → Today - Clinical sciences (Department)
Member
From15 Apr 2021 → 13 Feb 2022 - Internal medicine (Department)
Member
From1 Aug 2014 → 31 Jul 2017 - Faculty of Medicine and Pharmacy (Faculty)
Member
From27 Aug 2013 → 27 Jun 2019 - Faculty of Medicine and Pharmacy (Faculty)
Member
From19 Aug 2009 → 27 Jun 2013
Publications
1 - 9 of 9
- Phase II Trial Assessing the Repeatability and Tumor Uptake of [68Ga]Ga-HER2 Single-Domain Antibody PET/CT in Patients with Breast Carcinoma(2024)
Authors: Odrade Gondry, Vicky Caveliers, Catarina Xavier, Marian Vanhoeij, Guy Verfaillie, Christel Fontaine, Katrien Glorieus, Jacques De Grève, Sofie Joris, Ine Luyten, et al.
Pages: 178-184 - Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study(2023)
Authors: Sofie Joris, H. Denys, Joelle Collignon, M. Rasschaert, Daphne t'Kint de Roodenbeke, Francois P Duhoux, J-L Canon, S. Tejpar, J Mebis, Lore Decoster, et al.
- PRECISION(2022)
Authors: J Thouvenin, C Van Marcke, Lore Decoster, Gordana Raicevic, Kevin Punie, M. Vandenbulcke, R A Salgado, E Van Valckenborgh, Bart Maes, Sofie Joris, et al.
- Efficacy of a Flat Low Dose of Nivolumab in Advanced Cancer(2022)
Authors: Sofie Joris, Christel Fontaine, Lore Decoster, Jacques Vanderauwera, Kris Thielemans, Wim Waelput, Jacques De Grève
Pages: 1433-1437 - Real life safety and effectiveness of nivolumab in older patients with non-small cell lung cancer: Results from the Belgian compassionate use program(2020)
Authors: Sofie Joris, Thierry Pieters, Anne Sibille, Frederique Bustin, Laurence Jacqmin, HR Kalantari, VEERLE SURMONT, Jean-Charles Goeminne, frederic Clinckart, Karin Pat, et al.
Pages: 796-801 - The clinical characteristics of breast cancers with a familial risk in which no BRCA1/2 mutations were found are sometimes suggestive for a genetic etiology(2019)
Authors: Sofie Joris, Rajendra Bahadur Shahi, Sylvia De Brakeleer, Christel Fontaine, Maryse Bonduelle, Pauwels Ingrid, Erik Teugels, Jacques De Grève
- Retrospective comparison of two consecutive cohorts of adjuvant chemotherapy regimens of cyclophosphamide with either docetaxel or paclitaxel in older patients with early breast cancer.(2019)
Authors: Sofie Joris, Christel Fontaine, Lore Decoster, Leen Vanacker, Denis Schallier, Jacques De Grève
Pages: 663-666 - Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families(2019)
Authors: Rajendra Bahadur Shahi, Sylvia De Brakeleer, Ben Caljon, Ingrid Pauwels, Maryse Bonduelle, Sofie Joris, Christel Fontaine, Marian Vanhoeij, Sonia Van Dooren, Erik Teugels, et al.
- Frequent incidence of BARD1-truncating mutations in germline DNA from triple-negative breast cancer patients(2016)
Authors: Sylvia De Brakeleer, Jacques De Grève, C Desmedt, Sofie Joris, Christos Sotiriou, M. Piccart, I Pauwels, Erik Teugels
Pages: 336-340